Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.44 |
| ▸ | MERTK | Q12866 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL323126 | 0.85 | VCAM1 (0.64) | MAPTVCAM1TSHRHSD17B10CYP3A4 | |
| SCHEMBL7529832 | 0.83 | MAPT (0.53) | MAPTVCAM1TSHRHSD17B10CYP3A4 | |
| SCHEMBL4477143 | 0.82 | VCAM1 (0.70) | MAPTVCAM1TSHRCYP3A4HPGD | |
| SCHEMBL16953119 | 0.81 | MAPT (0.51) | MAPTVCAM1TSHRHSD17B10CYP3A4 | |
| SCHEMBL4385438 | 0.79 | VCAM1 (0.61) | MAPTVCAM1HPGDKAT2BMERTK | |
| SCHEMBL29336859 | 0.79 | MAPT (0.48) | MAPTVCAM1TSHRHSD17B10HPGD | |
| SCHEMBL16792376 | 0.79 | MAPT (0.61) | MAPTVCAM1TSHRHSD17B10MERTK | |
| SCHEMBL31176850 | 0.79 | MAPT (0.61) | MAPTVCAM1TSHRHSD17B10MERTK | |
| SCHEMBL1511983 | 0.78 | VCAM1 (0.59) | MAPTVCAM1KAT2BMERTKKMT2A | |
| SCHEMBL14220808 | 0.78 | VCAM1 (0.59) | MAPTVCAM1HPGDKAT2BMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112441983-A | Benzimidazole substituted nitrobenzene-based compound and preparation method thereof | 山东福长药业有限公司 | 2021-03-05 | — | — | CN | claimed |
| CN-115572243-B | Green preparation method of telmisartan key intermediate | 湖南大学 | 2025-06-13 | — | — | CN | disclosed |
| CN-115572243-B | Green preparation method of telmisartan key intermediate | 湖南大学 | 2025-06-13 | — | — | CN | disclosed |
| CN-112441983-B | Benzimidazole-substituted nitrobenzene-based compound and preparation method thereof | 山东福长药业有限公司 | 2023-09-15 | — | — | CN | disclosed |
| US-20230225201-A1 | Organic Light Emitting Diode and Device Comprising the Same | NOVALED GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| US-11555026-B2 | AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-01-17 | — | — | US | disclosed |
| CN-115572243-A | Green preparation method of telmisartan key intermediate | 湖南大学 | 2023-01-06 | — | — | CN | disclosed |
| CN-115572243-A | Green preparation method of telmisartan key intermediate | 湖南大学 | 2023-01-06 | — | — | CN | disclosed |
| US-20220267276-A1 | NLRP MODULATORS | NOVARTIS INFLAMMASOME RESEARCH, INC. | 2022-08-25 | — | — | US | disclosed |
| EP-3817817-A1 | NLRP MODULATORS | Novartis AG (CH) | 2021-05-12 | — | — | EP | disclosed |
| WO-1998024784-A1 | SUBSTITUTED SULFONIC ACID N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| EP-0832066-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0832065-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5731315-A | Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-03-24 | — | — | US | disclosed |
| CN-1140709-A | Substituted N- (indole-2-carbonyl) -beta-alaninamides and derivatives as antidiabetics | PFIZER (US) | 1997-01-22 | — | — | CN | disclosed |
| WO-1996040679-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996039385-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| EP-0655439-A2 | 5,6-Bicyclic glycoprotein IIb IIIa antagonists useful in inhibition of platelet aggregation | ELI LILLY AND COMPANY (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5034410-A | Nitrile and oxo containing amides or thioamides | SYNTEX (U.S.A.) INC. (US) | 1991-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555026-B2 | AHR inhibitors and uses thereof | AHR, ARNT, AIPL1 | MAPT 4714/4885VCAM1 2142/4885TSHR 1220/4885 |
| US-20220267276-A1 | NLRP MODULATORS | NLRP1, NRP1, NR4A3 | MAPT 3301/4885VCAM1 1253/4885TSHR 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.